As of 2024-12-14, the Relative Valuation of OncoCyte Corp (OCX) is (46.50) USD. This relative valuation is based on P/E multiples. With the latest stock price at 2.39 USD, the upside of OncoCyte Corp based on Relative Valuation is -2045.6%.
The range of the Relative Valuation is (44.42) - (48.99) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 17.3x - 24.4x | 17.5x |
| Forward P/E multiples | 12.5x - 19.1x | 18.8x |
| Fair Price | (44.42) - (48.99) | (46.50) |
| Upside | -1958.8% - -2149.6% | -2045.6% |
| Date | P/E |
| 2024-11-20 | -1.07 |
| 2024-11-19 | -1.00 |
| 2024-11-18 | -1.03 |
| 2024-11-15 | -1.02 |
| 2024-11-14 | -1.09 |
| 2024-11-13 | -1.15 |
| 2024-11-12 | -1.17 |
| 2024-11-11 | -1.13 |
| 2024-11-08 | -1.12 |
| 2024-11-07 | -1.11 |
| 2024-11-06 | -1.11 |
| 2024-11-05 | -1.14 |
| 2024-11-04 | -1.13 |
| 2024-11-01 | -1.17 |
| 2024-10-31 | -1.18 |
| 2024-10-30 | -1.18 |
| 2024-10-29 | -1.21 |
| 2024-10-28 | -1.21 |
| 2024-10-25 | -1.19 |
| 2024-10-24 | -1.19 |
| 2024-10-23 | -1.23 |
| 2024-10-22 | -1.20 |
| 2024-10-21 | -1.22 |
| 2024-10-18 | -1.22 |
| 2024-10-17 | -1.22 |
| 2024-10-16 | -1.21 |
| 2024-10-15 | -1.22 |
| 2024-10-14 | -1.22 |
| 2024-10-11 | -1.19 |
| 2024-10-10 | -1.21 |
| 2024-10-09 | -1.20 |
| 2024-10-08 | -1.19 |
| 2024-10-07 | -1.17 |
| 2024-10-04 | -1.13 |
| 2024-10-03 | -1.16 |
| 2024-10-02 | -1.19 |
| 2024-10-01 | -1.17 |
| 2024-09-30 | -1.11 |
| 2024-09-27 | -1.12 |
| 2024-09-26 | -1.16 |
| 2024-09-25 | -1.14 |
| 2024-09-24 | -1.17 |
| 2024-09-23 | -1.23 |
| 2024-09-20 | -1.30 |
| 2024-09-19 | -1.17 |
| 2024-09-18 | -1.15 |
| 2024-09-17 | -1.21 |
| 2024-09-16 | -1.23 |
| 2024-09-13 | -1.20 |
| 2024-09-11 | -1.21 |